Evidence map›Paper›PMID 36800099›Full record

ArticleOncology and therapy2023

Development of a Conceptual Model of the Patient Experience in Small Cell Lung Cancer: A Qualitative Interview Study.

Danielle E Altman, Xinke Zhang, An-Chen Fu, Alissa R Rams, Jessica A Baldasaro, Samir Ali Ahmad, Michael Schlichting, Patrick Marquis, Elena Benincasa, Camilo Moulin and 1 more

Open access · goldAbstract read
In one paragraph

Article in Oncology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Danielle E AltmanModus Outcomes, a Division of THREAD, Cambridge, MA, USA. danielle.altman@threadresearch.com.ORCID http://orcid.org/0000-0003-4222-4662
Xinke ZhangJanssen Real World Value & Evidence at Johnson & Johnson, New Brunswick, NJ, USA.
An-Chen FuEMD Serono Research & Development Institute, an Affiliate of Merck KgaA, Billerica, MA, USA.
Alissa R RamsModus Outcomes, a Division of THREAD, Cambridge, MA, USA.
Jessica A BaldasaroModus Outcomes, a Division of THREAD, Cambridge, MA, USA.
Samir Ali AhmadModus Outcomes, a Division of THREAD, Cambridge, MA, USA.
Michael SchlichtingMerck KGaA, Darmstadt, Germany.
Patrick MarquisModus Outcomes, a Division of THREAD, Cambridge, MA, USA.
Elena BenincasaMerck KGaA, Darmstadt, Germany.
Camilo MoulinMerck KGaA, Darmstadt, Germany.
Vivek PawarEMD Serono Research & Development Institute, an Affiliate of Merck KgaA, Billerica, MA, USA.
Merck (Germany) · DEResearch & Development Institute · USAltrecht GGZ · NLJohnson & Johnson (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSmall cell lung cancer (SCLC) is a subtype of lung cancer, the second most common cancer diagnosis worldwide. Currently, there is little published qualitative research that provides insight into the disease-related symptoms and impacts that are relevant to patients living with SCLC as directly reported by patients themselves.

methodsThis qualitative, cross-sectional, noninterventional, descriptive study included concept elicitation interviews with participants diagnosed with SCLC and the development of a conceptual model of clinical treatment benefit.

resultsConcept elicitation interview data from 26 participants with SCLC were used to develop a conceptual model of clinical treatment benefit that organized 28 patient-reported concepts into two domains: disease-related symptoms (organ-specific and systemic) and impacts. Organ-specific symptoms included cough, chest pain, and difficulty breathing. Systemic symptoms included pain, fatigue, appetite loss, and dizziness. Impacts included physical functioning, role functioning, reduced movement, impact on sleep, and weight loss.

conclusionAs evidenced by this study, people with SCLC experience considerable and significant symptoms and impacts, including physical and role functioning challenges, that affect their quality of life. This conceptual model will inform the design of a patient-reported outcome (PRO) questionnaire for a future SCLC clinical trial, helping to establish the content validity of the items and questionnaires used in the trial and ensuring that the questionnaires and items selected are appropriately targeted to the population. This conceptual model could also be used to inform future SCLC clinical trials.

Indexed as

Patient-reported outcomesQualitative researchSmall cell lung cancer

Identifiers

PMID36800099
PMCPMC10260713
OpenAlexW4321168892

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.